A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure

Trial Profile

A Large Scale Clinical Trial Testing the Effects of n-3 PUFA and Rosuvastatin on Mortality-Morbidity of Patients With Symptomatic Congestive Heart Failure

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2015

At a glance

  • Drugs Rosuvastatin (Primary) ; Omega-3-acid ethyl esters
  • Indications Chronic heart failure; Heart failure
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms GISSI-HF
  • Most Recent Events

    • 20 Nov 2013 Results for the prognostic impact of metabolic syndrome presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 20 Nov 2013 Pooled results for competing risks for fatal/non-fatal myocardial infarction (MI), fatal/non-fatal stroke, other CV death, and non-CV death presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 17 Nov 2013 Results of an analysis investigating the effect of bodyweight changes in outcomes presented at the 86th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top